Biliary cancer
Drug research and approvals for biliary cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 227 studies of biliary cancer are recruiting on ClinicalTrials.gov, and Health Canada has authorized 12 drug trials for it since 2013.
- Recruiting worldwide: 227
- Trials authorized in Canada: 12
- FDA orphan approvals: 0
- EU medicines: 0
- Photodynamic Therapy Combined With a Self-expandable Radioactive Particle-loaded Biliary Stent for Unresectable…NCT07916870 · Not applicable · Zhai Wenlong · starts May 30, 2025
- CR-002 in Adult Participants With Locally Advanced or Metastatic Solid TumorsNCT07909031 · Phase 1 / Phase 2 · Crescent Biopharma, Inc. · starts Oct 21, 2026
- Phase II Study of Primary Tumor Resection and Selective Lymph Node Dissection Followed by RT for BTC With Lymph Node…NCT07893392 · Phase 2 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences · starts Oct 8, 2026
- Incidental Gallbladder Carcinoma :Incidence and Clinical Significance in Specimens From Routine Cholecystectomies in…NCT07885800 · Not reported · Sohag University · starts Sep 20, 2026
- SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-METNCT07873450 · Phase 1 / Phase 2 · Full-Life Technologies UK Limited · starts Dec 1, 2026
- Prevention of Bile Leakage After Liver Resection in ChildrenNCT07867522 · Not applicable · Federal Research Institute of Pediatric Hematology, Oncology and Immunology · starts Feb 10, 2026
- Histotripsy in Biliary Tract CancerNCT07853690 · Not applicable · NYU Langone Health · starts Oct 5, 2026
- A Phase II Study of Ivonescimab in Combination With GEMOX as Neoadjuvant and Conversion Therapy for Biliary Tract CancerNCT07854600 · Phase 2 · Haitao Zhao, MD · starts Oct 1, 2026
- A Prospective Study of Sacituzumab Tirumotecan Plus Pembrolizumab for Advanced Biliary Tract CancerNCT07850791 · Phase 2 · Haitao Zhao, MD · starts Oct 1, 2026
How its trials ended
383 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 83 whose ending is known, 37% met their primary endpoint, 11% missed it and 52% stopped early.
- Ongoing15841%
- Completed, result not reported7820%
- Status unknown6417%
- Met its primary endpoint318%
- Stopped: other or unclear195%
- Missed its primary endpoint92%
- Stopped: lack of efficacy92%
- Stopped: enrollment or feasibility92%
- Stopped: sponsor or business decision51%
- Stopped: funding1<1%
| Oct 29, 2026 | A phase 2, open-label, master protocol study to evaluate safety and efficacy of treatment combinations with telisotuzumab adizutecan in subjects with…Telisotuzumab adizutecan (ABBV-400) / Gemcitabine | AbbVie | Pending |
| Oct 22, 2025 | Phase III, randomized, open-label, global, multicenter study of rilvegostomig or durvalumab in combination with chemotherapy as a first-line treatment for…Imfinzi / Rilvegostomig | AstraZeneca Pharmaceuticals | Ongoing |
| May 30, 2024 | Beamion pantumor-1: a phase II, multicentre, multicohort, open label trial to evaluate the efficacy and safety of oral zongertinib (bi 1810631) for the…Zongertinib (bi 1810631) | Boehringer Ingelheim (Canada) Ltd Ltee | Ongoing |
| Mar 26, 2024 | A phase 1b study evaluating the safety, tolerability, pharmacokinetics, and efficacy of amg 193 in combination with other therapies in subjects with advanced…Amg 193 | Amgen | Pending |
| Jul 7, 2021 | A first in human, open label, dose escalation phase I study evaluating the safety, pharmacokinetics, and preliminary clinical activity profile of single agent…RO7119929 / Tocilizumab (RO4877533) | Roche | Pending |
| Dec 8, 2020 | A phase II randomized, double-blind placebo-controlled study of atezolizumab with or without bevacizumab in combination with cisplatin plus gemcitabine in…Tecentriq / Avastin | Roche | Closed |
| Aug 21, 2019 | "a phase 3 randomized, double blind study of pembrolizumab plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin as first-line therapy in…Keytruda (MK-3475) / Cisplatin / Gemcitabine | Merck & Co. (MSD) | Ongoing |
| May 23, 2019 | Phase III open-label, multi-centre, randomised study comparing NUC-1031 plus cisplatin to gemcitabine plus cisplatin in patients with previously untreated…Fosgemcitabine palabenamide (NUC-1031)/ Gemcitabine/ Cisplatin | NuCana | Closed |
| Nov 3, 2015 | A multicentre, open-label phase II study of nab-paclitaxel in combination with gemcitabine + cisplatin as first line treatment in patients with unresectable…Paclitaxel/ Gemcitabine/ Cisplatin | Cross Cancer Institute - Cancer Care Alberta | Ongoing |
| Jun 27, 2014 | A randomized phase II trial of mek inhibitor selumetinib (AZD6244) combined continuously or sequentially with cisplatin/gemcitabine (cis/gem) versus cis/gem…Selumetinib/ Cisplatin/ Gemcitabine | Princess Margaret Cancer Centre | Closed |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA